Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NP-50301
- Development stage
- Discontinued
- Lead developer
- Nascent Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Topical, Ophthalmic
01
Overview
NP-50301 is a small molecule ophthalmic therapeutic developed as a topical eye drop formulation of an estrogen ester compound. Its primary mechanism of action is as an agonist of estrogen receptor. The drug was developed for the treatment of post-menopausal Dry Eye Syndrome (DES) and xerophthalmia. Development was led by Nascent Pharmaceuticals and Xiamen Nanxun Co., Ltd. Clinical development reached up to Phase 2 trials but has since been discontinued[1][2][3].
02
Targets
ER (Estrogen receptor)
Beyond the preview
Go deeper on NP-50301.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NP-50301.